| Balance Sheets | 2025-09-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 10,354,773 | |||
| Grant receivable | 9,825 | |||
| Prepaid expenses | 170,771 | |||
| Total current assets | 10,535,369 | |||
| Loan commitment fees | 165,670 | |||
| Total assets | 10,701,039 | |||
| Accounts payable | 607,539 | |||
| Accrued expenses | 356,282 | |||
| Total liabilities | 963,821 | |||
| Common stock, 0.001 par value 75,000,000 shares authorized and 41,084,731 shares issued and outstanding at september 30, 2025 and june 30, 2025 | 41,086 | |||
| Additional paid-in capital | 85,742,993 | |||
| Accumulated deficit | -76,046,861 | |||
| Total stockholders equity | 9,737,218 | |||
| Total liabilities and stockholders equity | 10,701,039 | |||
Anebulo Pharmaceuticals, Inc. (ANEB)
Anebulo Pharmaceuticals, Inc. (ANEB)